Latest News and Press Releases
Want to stay updated on the latest news?
-
IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Habit is rolling out a Fresh New Menu packed with limited-time offers, reimagined favorites, and new core menu additions. From coastal-inspired...
-
Dublin, Feb. 12, 2026 (GLOBE NEWSWIRE) -- The "Negotiation Skills for Contracts and Commercial Managers Training Course (Mar 16, 2026)" training has been added to ResearchAndMarkets.com's offering....
-
Biotricity Delivers Strong Q3 Fiscal 2026 Performance, Growing Revenue Momentum and Expanding EBITDA
REDWOOD CITY, CA, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company”), an innovative Technology-as-a-Service (TaaS) company committed to transforming...
-
Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate®, a blockbuster orphan therapy in corneal diseaseDr. Mantelli...
-
Dublin, Feb. 05, 2026 (GLOBE NEWSWIRE) -- The "Frost Radar: Workforce Engagement Management, 2025" report has been added to ResearchAndMarkets.com's offering.A Benchmarking System to Spark...
-
Dublin, Feb. 04, 2026 (GLOBE NEWSWIRE) -- The "Interactive Kiosk Market by Information & Directory, Bitcoin, Ordering & Retail, Ticketing & Reservation, Hospitality & Travel, Public...
-
Dublin, Jan. 30, 2026 (GLOBE NEWSWIRE) -- The "Understanding and Managing Contracts to Achieve Better Results Training Course (April 15-16, 2026)" training has been added to ...
-
New research reveals that nearly half of Canadians (49 per cent) are planning to dine out this Valentine’s Day151 per cent of Canadians believe Valentine’s Day is becoming more about celebrating all...
-
Dublin, Jan. 20, 2026 (GLOBE NEWSWIRE) -- The "Malaysia Foodservice - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ...
-
BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3...